Neurolief Appoints Dr. Owen Muir as Chief Medical Officer to Drive Innovation in Depression Treatment

"We are excited to welcome Dr. Muir to our leadership team," said Scott Drees, CEO of Neurolief. "His extensive expertise in brain stimulation therapies, combined with his dedication to advancing mental health treatment, aligns perfectly with Neurolief's mission. We are confident that Dr. Muir's leadership will be pivotal to the successful commercial launch of Proliv™Rx, providing access to this groundbreaking therapy for the millions of patients who have not found relief with traditional antidepressants."

TAMPA, Fla., 05/02/2025 (informazione.news - comunicati stampa - information technology)

said Scott Drees , CEO of Neurolief. ™

Dr. Muir's appointment comes at a pivotal time for Neurolief as the company prepares to launch its latest brain stimulation therapy, ™ designed for Treatment-Resistant Depression (TRD). This FDA-Breakthrough Designated therapy is the first at-home brain stimulation solution to demonstrate clinical success in a controlled trial for patients who have not responded to traditional therapies, marking a significant advancement in mental health care.

Proliv™Rx represents a breakthrough in non-invasive brain neuromodulation therapy, designed for administration both in clinical settings and the comfort of patient's homes.  Utilizing three adaptive output channels, Proliv™Rx delivers targeted electrical pulses through key neural pathways, stimulating brain regions associated with mood regulation.

Complementing its advanced brain stimulation capabilities, Proliv™Rx integrates an interactive patient mobile app and cloud-enabled data tracking system. This connected ecosystem empowers physicians to remotely monitor patient progress, analyze their data and personalize treatment, ultimately driving improved therapeutic outcomes.

Neurolief is a pioneering neuromodulation company dedicated to developing innovative therapies for mental health and neurological disorders. The company developed the world's first non-invasive, multi-channel brain stimulation technology, designed to simultaneously target multiple neural pathways in the head, modulating brain regions involved in mood and pain regulation. Neurolief's Relivion MG therapy is currently approved in the USA , Europe , and Japan for the treatment of migraine.

For more information, please visit www.neurolief.com.

View original content:https://www.prnewswire.co.uk/news-releases/neurolief-appoints-dr-owen-muir-as-chief-medical-officer-to-drive-innovation-in-depression-treatment-302368224.html